drugset / Trial / NCT00612573

Treatment of Moderate to Severe Facial Acne Vulgaris

NCT00612573

Phase 2 Completed 257 enrolled Warner Chilcott
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Randomized, multi-center, double-blind, placebo-controlled 12-week study to assess the safety and efficacy of 3 doses of an oral formulation of Doxycycline oral tablets using the Investigator's Global Assessment (IGA) score and the absolute change from baseline in inflammatory lesion count in patients with moderate to severe facial acne vulgaris. Additionally, the absolute change from baseline in non-inflammatory and total lesions of the active study medication to placebo will be evaluated.

Timeline

Start
2008-02
Primary completion
2008-11
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxycycline Small molecule 0.6 mg/kg Oral
Subject Doxycycline Small molecule 1.2 mg/kg Oral
Subject Doxycycline Small molecule 2.4 mg/kg Oral

Indications